Centessa Pharmaceuticals Shares Rise After $225M Public Offering

Dow Jones09-13

By Chris Wack

Centessa Pharmaceuticals shares rose 14% to $17.19 after the company priced an underwritten public offering of 15.3 million American Depositary shares, each representing one ordinary share, at $14.75 per ADS.

The clinical-stage pharmaceutical company expects to see proceeds from this offering of $225 million.

All ADSs sold in the offering were offered by the Boston-based Centessa.

The offering is expected to close on or about Monday.

Centessa has granted the underwriters a 30-day option to buy up to an additional 2.3 million ADSs at the public offering price, less underwriting discounts and commissions.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

September 13, 2024 10:55 ET (14:55 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467077490?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-13 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467077490","market":"nz","top_or_hot":-1,"title":"Centessa Pharmaceuticals Shares Rise After $225M Public Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Centessa Pharmaceuticals shares rose 14% to $17.19 after the company priced an underwritten public offering of 15.3 million American Depositary shares, each representing one ordinary share, at $14.75 per ADS. \n</p>\n<p>\n  The clinical-stage pharmaceutical company expects to see proceeds from this offering of $225 million. \n</p>\n<p>\n  All ADSs sold in the offering were offered by the Boston-based Centessa. \n</p>\n<p>\n  The offering is expected to close on or about Monday. \n</p>\n<p>\n  Centessa has granted the underwriters a 30-day option to buy up to an additional 2.3 million ADSs at the public offering price, less underwriting discounts and commissions. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 13, 2024 10:55 ET (14:55 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Centessa Pharmaceuticals Shares Rise After $225M Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentessa Pharmaceuticals Shares Rise After $225M Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-13 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Chris Wack \n\n\n \n\n\n  Centessa Pharmaceuticals shares rose 14% to $17.19 after the company priced an underwritten public offering of 15.3 million American Depositary shares, each representing one ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2467077490","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467077490","pubTimestamp":1726239300,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Centessa Pharmaceuticals shares rose 14% to $17.19 after the company priced an underwritten public offering of 15.3 million American Depositary shares, each representing one ordinary share, at $14.75 per ADS.The clinical-stage pharmaceutical company expects to see proceeds from this offering of $225 million.All ADSs sold in the offering were offered by the Boston-based Centessa.The offering is expected to close on or about Monday.Centessa has granted the underwriters a 30-day option to buy up to an additional 2.3 million ADSs at the public offering price, less underwriting discounts and commissions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CNTA":"Centessa Pharmaceuticals plc","BK4539":"次新股","BK4535":"淡马锡持仓"},"translate_title":"Centessa Pharmaceuticals公开发行2.25亿美元后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTA":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Centessa Pharmaceuticals shares rose 14% to $17.19 after the company priced an underwritten public offering of 15.3 million American Depositary shares, each representing one ordinary share, at $14.75 per ADS. \n\n\n  The clinical-stage pharmaceutical company expects to see proceeds from this offering of $225 million. \n\n\n  All ADSs sold in the offering were offered by the Boston-based Centessa. \n\n\n  The offering is expected to close on or about Monday. \n\n\n  Centessa has granted the underwriters a 30-day option to buy up to an additional 2.3 million ADSs at the public offering price, less underwriting discounts and commissions. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 13, 2024 10:55 ET (14:55 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467077490"}